Aura Biosciences, Inc. Overview
Pro stress-test →Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Strategic Profile
Pro stress-test →The company's lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is positioned to address unmet needs in ophthalmologic and urologic cancers using precision photodynamic therapy technology to selectively target tumor cells while preserving healthy tissue.
Competitive Landscape
Pro stress-test →Aura competes in the rare cancer and precision oncology space with companies developing novel therapeutic approaches for unmet needs. The vision-sparing focus for choroidal melanoma represents a differentiated niche, though the broader oncology market is highly competitive with established pharma players and numerous clinical-stage biotechs pursuing similar indications.
Industry Context
Aura Biosciences, Inc. operates in Biotechnology/Oncology.
Key facts
Founded: 2009 · Headquarters: Boston, Massachusetts · Market cap: $336.6M